This poster describes the differences in acceptance and barriers of the Human Papilloma Virus (HPV) vaccination between the United States and several European Nations. Since the marketing of Gardasil and Cervarix, knowledge about HPV infections and cervical cancer has increased. Yet, vaccination rates are lower than expected despite funded programs in both geographical areas. A systematic review of empirical studies, governmental and health organizations’ data provides the primary sources on the subject of acceptance and barriers of HPV vaccination. Neither the United States nor European nations keep track of acceptance and barriers of HPV vaccinations. Partial reporting of the HPV vaccination rates provides an incomplete account in both geographical areas. Studies lack consistency in the way they were carried out, the questions asked, data evaluation, and selection of population. The results of earlier research studies do not differ much from the results of later studies. Later research mostly confirms previous studies and does not add new findings to the topic. Acceptance of HPV vaccination is fairly high in all countries. This does not indicate that women act upon the availability of HPV vaccination. Barriers are difficult to assess due to intangible perceptions and vague assumptions. Cost of the HPV vaccination, safety, efficacy, concern over side-effects, the three doses requirement, lack of information, and distrust presented the greatest barriers. Mandatory HPV vaccination and a comprehensive, standardized, and consistent reporting system on HPV vaccination rates may promote the uptake of HPV vaccination.